

## Cannabis for Symptom Control #279

Sunil K. Aggarwal, MD, PhD and Craig D. Blinderman, MD, MA

### Background

**T**HE USE OF CANNABIS (marijuana) for medical purposes has become legalized in many U.S. states and Canada. This *Fast Fact* reviews the use of plant-based cannabis preparations to treat symptoms associated with advanced illness. *Fast Fact* #93 reviewed the use of prescription single molecule cannabinoid medications.

### Legal Issues

A number of countries have implemented pharmacy stocking and dispensing systems for herbal cannabis and/or oral cannabis extracts, available to patients by prescription. Nabiximols (Sativex<sup>®</sup>), a specific cannabis extract made by combining liquid CO<sub>2</sub> extracts of two strains of herbal cannabis, has been approved for prescription use in multiple countries for a variety of symptom indications. Cannabis is an “investigational new drug” in the United States. It is classified as a Schedule I controlled substance in the United States, making federally legal prescribed use by patients extremely rare and only under investigational circumstances. In recent decades, however, an increasing number of U.S. states have legalized cannabis for medical use. Since 2012, some states have legalized it for recreational/unrestricted personal use by adults. State medical cannabis programs allow authorized patients to obtain cannabis from dispensaries, and others allow personal or collective cultivation for medicinal use. In all states with the exception of California and Massachusetts, patients who qualify for medical cannabis must have prespecified chronic, debilitating, or terminal illness diagnoses; however, in no state is cannabis considered an FDA-approved treatment for any medical condition. Providers must be familiar with their own state’s laws and regulatory climate around authorizing cannabis use.<sup>1</sup>

### Pharmacology

There are a large number of cannabis strains used medically; each may vary by morphology, odor, and chemotype,

producing plant resin with varying ratios of pharmacologically active cannabinoids, principally tetrahydrocannabinol (THC) and cannabidiol (CBD), terpenoids, flavonoids, and other molecules. Although other receptors play a role, the majority of the effects of THC from cannabis are mediated through partial agonism of central and peripheral cannabinoid receptors.<sup>2</sup> Cannabinoid receptors (CB1, CB2) are part of the endocannabinoid system, a prohomeostatic modulatory system composed of several endogenous ligands.<sup>3</sup> Physiologically, the endocannabinoid signalling system (ECS) has been shown to impact pain perception, movement, appetite, aversive memory extinction, hypothalamic-pituitary-adrenal (stress) axis modulation, immune function, mood, inflammation, and others.<sup>4</sup> THC is excreted via both hepatic and renal mechanisms. No specific studies have been done with cannabis-based medicines in patients with significant hepatic or renal impairment, but it can be expected that effects would be more exaggerated or prolonged in these settings.<sup>5</sup> Given that cannabinoids are highly protein bound in the plasma, it is unlikely they will be effectively removed by hemodialysis.<sup>6</sup>

### Dosing

Exact dosages depend on individual patient need and tolerance of side effects. Cannabis preparations include resin-containing herbal flowers, which can be heated and delivered to the lungs via inhalation of smoke or vapor, and cannabis-based extracts, which include oral, oromucosal, rectal, and topically delivered preparations in the form of concentrates, suppositories, edibles, and salves. Because cannabinoids are volatile, they will vaporize at a temperature much lower than actual combustion, and can be inhaled without the generation of potentially harmful smoke.<sup>7</sup> Cannabinoids are lipophilic and have nearly immediate onset of action when smoked or vaporized. Vaporization has the advantage of rapid onset of effect and easy dose titration, as the patient can slowly increase use to achieve desired therapeutic effect. Patients can be advised to pause briefly between inhalations to ascertain effectiveness of the medicine and to stop when maximum effect is

---

*Fast Facts and Concepts* are edited by Drew A. Rosielle, MD (University of Minnesota Medical School and Fairview Health Services) and Sean Marks, MD (Medical College of Wisconsin), and are published by the End of Life/Palliative Education Resource Center at the Medical College of Wisconsin. For more information write to: [rosielle@umn.edu](mailto:rosielle@umn.edu). More information, as well as the complete set of *Fast Facts*, are available at EPERC: [www.mcw.edu/eperc](http://www.mcw.edu/eperc).

Copyright/Referencing Information: Users are free to download and distribute *Fast Facts* for noncommercial educational purposes only. Available at: [www.eperc.mcw.edu/fastfact/ff\\_279.htm](http://www.eperc.mcw.edu/fastfact/ff_279.htm).

Disclaimer: *Fast Facts and Concepts* provide educational information. This information is not medical advice. Health care providers should exercise their own independent clinical judgment. Some *Fast Facts* cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.

achieved. Oral ingestion of cannabis products has a delayed onset of action compared to inhalation and titration is more difficult. Maximum cannabinoid blood levels are reached up to six hours post oral ingestion, with a half-life of 20 to 30 hours.<sup>4</sup>

### Side Effects/Risks

Cannabis use can cause xerostomia, palpitations, flushing, nausea, confusion, anxiety, dysphoria, and acute toxic psychosis. Cannabis ingestion raises the risk of a motor vehicle accident.<sup>8</sup> Epidemiological data from nonmedical settings suggest an association between chronic cannabis use history and schizophrenia, but the causal direction of this link has not been established.<sup>9,10</sup>

### Indications

Over the last several decades cannabis and cannabinoid therapeutics have been studied in over 100 controlled clinical trials of varying size and quality, investigating a wide range of conditions.<sup>11</sup> As with the evidence base for most pharmacologic symptom interventions, there are a lack of comparative data between cannabis and other commonly used treatments for example for spasticity or neuropathic pain. Of relevance to palliative care settings,<sup>12–15</sup> cannabis medicines, both orally administered and inhaled, have been shown to have efficacy in randomized, double-blind, placebo-controlled trials (RCT) for a number of symptoms. For *cancer pain*, a multicenter RCT, involving 360 patients, investigated oral cannabis to treat breakthrough cancer pain in subjects who were started on a long-acting opioid. It showed analgesic efficacy in the low and medium dose ranges, which were also well tolerated.<sup>16</sup> Three RCTs, involving 43 subjects in total, investigating inhaled cannabis for nausea and vomiting secondary to active cancer chemotherapy, demonstrated inhaled cannabis to be an efficacious antiemetic.<sup>17–19</sup> For multiple sclerosis, numerous symptoms—spasticity, both objective and subjectively assessed, spasm frequency, insomnia, pain, as well as impaired mobility—were shown to be improved in a 630-subject multicenter RCT over a 12-month period.<sup>20</sup> Three RCTs of inhaled cannabis involving 107 subjects in total congruently showed efficacy for appetite stimulation and weight gain in patients with AIDS wasting syndromes,<sup>21–23</sup> and two RCTs of inhaled cannabis for painful HIV sensory neuropathy involving 89 subjects in total both showed significant analgesic efficacy,<sup>24,25</sup> with a combined number-needed-to-treat of 3.38, superior to all other medications similarly tested for this indication.<sup>26</sup> Three additional RCTs involving 100 subjects in total—of inhaled cannabis for chronic, intractable neuropathic pain due to multiple etiologies—all congruently showed efficacy for smoked and vaporized cannabis.<sup>27–29</sup>

### References

1. Aggarwal SK, et al.: Clearing the air: What the latest Supreme Court decision regarding medical marijuana really means. *Am J Hosp Palliat Care* 2005;22:327–329.
2. Russo EB: Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 2011;163:1344–1364.
3. Wilson RI, Nicoll RA: Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. *Nature* 2001; 410:588–592.

4. Aggarwal SK: Cannabinergic pain medicine: A concise clinical primer and survey of randomized-controlled trial results. *Clin J Pain* 2013;29:162–171.
5. GW Pharma: Special warnings and precautions for use. In: Summary of Product Characteristics: Sativex Oromucosal Spray. GW Pharma, Wiltshire, England, 2012.
6. Davison SN, et al.: Is there a legitimate role for the therapeutic use of cannabinoids for symptom management in chronic kidney disease? *J Pain Symptom Manage* 2011;41:768–778.
7. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R: Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. *J Pharm Sci* 2006;95:1308–1317.
8. Elvik R: Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. *Accid Anal Prev* 2013;60:254–267.
9. Advisory Council on the Misuse of Drugs: Further consideration of the classification of cannabis under the Misuse of Drugs Act 1971. London: Home Office, 2005.
10. Advisory Council on the Misuse of Drugs: Cannabis: Classification and public health. London: Home Office, 2008.
11. Hazekamp A, Grotenhermen F: Review on clinical studies with cannabis and cannabinoids 2005–2009. *Cannabinoids* 2010;5:1–21.
12. Carter GT, et al.: Cannabis in palliative medicine: Improving care and reducing opioid-related morbidity. *Am J Hosp Palliat Care* 2011;28:297–303.
13. Shaiyova L, et al.: Cancer pain: Principles of assessment and syndromes. In: Berger AM, Shuster JL, Von Roenn JH (eds): *Principles and Practice of Palliative Care and Supportive Oncology, 4th ed.* Philadelphia, PA. Lippincott Williams & Wilkins, 2013.
14. Aggarwal SK, et al.: Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. *J Opioid Manag* 2009;5:257–286.
15. Aggarwal SK, et al.: Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. *Am J Hosp Palliat Care* 2013;30:523–531.
16. Portenoy RK, et al.: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. *J Pain* 2012;13: 438–449.
17. Chang AE, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: A prospective, randomized evaluation. *Ann Intern Med* 1979;91:819–824.
18. Chang AE, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer* 1981;47: 1746–1751.
19. Levitt M, et al.: Randomized double-blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics. *Proc Am Soc Clin Oncol* 1984;3:91(abstr C-354).
20. Zajicek J, et al.: Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. *J Neurol Neurosurg Psychiatry* 2005;76:1664–1669.
21. Abrams DI, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection. *Ann Intern Med* 2003;139:258–266.
22. Haney M, et al.: Dronabinol and marijuana in HIV+ marijuana smokers: Acute effects on caloric intake and mood. *Psychopharmacology* 2005;181:170–178.

23. Haney M, et al.: Dronabinol and marijuana in HIV-positive marijuana smokers. *J Acquir Immune Defic Syndr* 2007;45: 545–554.
24. Abrams DI, et al.: Cannabis in painful HIV-associated sensory neuropathy. *Neurology* 2007; 68:515–521.
25. Ellis RJ, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. *Neuropsychopharmacology* 2009;34:672–680.
26. Phillip TJ, et al.: Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials. *PLoS One* 2010;5:e14433.
27. Wilsey B, et al.: A randomized, placebo-controlled crossover trial of cannabis cigarettes in neuropathic pain. *J Pain* 2008;9:506–521.
28. Ware MA, et al.: Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. *CMAJ* 2010;182: E694–E701.
29. Wilsey B, et al.: Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain* 2013;14:136–148.

Address correspondence to:  
*Sunil K. Aggarwal, MD, PhD*  
*Department of Physical Medicine and Rehabilitation*  
*New York University*  
*240 East 38<sup>th</sup> Street*  
*15<sup>th</sup> Floor, Room 15-82*  
*New York, NY 10016*  
*E-mail: humansunil@gmail.com*